Á lódáil...
Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab
Adalimumab is a fully humanized anti-tumor necrosis factor alpha monoclonal antibody that was recently granted regulatory approval in the USA for the treatment of moderate to severe Crohn’s disease (CD) in children. Like infliximab, the first biologic agent used to treat pediatric CD, regulatory app...
Na minha lista:
| Foilsithe in: | Pediatric Health Med Ther |
|---|---|
| Main Authors: | , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Dove Medical Press
2015
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5683269/ https://ncbi.nlm.nih.gov/pubmed/29388607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PHMT.S40948 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|